{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:44:40Z","timestamp":1787773480277,"version":"build-2784847793"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10557-025-07690-5","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:01:50Z","timestamp":1748664110000},"page":"561-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Application of Machine Learning in Warfarin Dose Precision for Diabetic Patients Treated with Statins: A Comparative Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Mobina","family":"Ghajar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana Sadat","family":"Ghafourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tarkiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atousa Naser","family":"Tork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7952-3009","authenticated-orcid":false,"given":"Amin","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz","family":"Zolfaghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ghasemi","family":"Palangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"7690_CR1","doi-asserted-by":"crossref","first-page":"1320938","DOI":"10.3389\/fcvm.2023.1320938","volume":"10","author":"M Wang","year":"2023","unstructured":"Wang M, Qian Y, Yang Y, Chen H, Rao WF. Improved stacking ensemble learning based on feature selection to accurately predict warfarin dose. Front Cardiovasc Med. 2023;10:1320938.","journal-title":"Front Cardiovasc Med"},{"key":"7690_CR2","doi-asserted-by":"crossref","unstructured":"Petch J, Nelson W, Wu M, Ghassemi M, Benz A, Fatemi M, et al. Optimizing warfarin dosing for patients with atrial fibrillation using machine learning. Scientific Reports. 2024;14.","DOI":"10.1038\/s41598-024-55110-9"},{"issue":"4","key":"7690_CR3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/hrt.2004.042465","volume":"91","author":"M Jones","year":"2005","unstructured":"Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91(4):472\u20137.","journal-title":"Heart"},{"issue":"1","key":"7690_CR4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12933-020-01005-8","volume":"19","author":"YH Chan","year":"2020","unstructured":"Chan YH, Chuang C, Chan CC, Lee HF, Huang YC, Huang YT, et al. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation. Cardiovasc Diabetol. 2020;19(1):30.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"7690_CR5","first-page":"812","volume":"114","author":"WS Chung","year":"2015","unstructured":"Chung WS, Lin CL, Kao CH. Diabetes increases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study Thromb Haemost. 2015;114(4):812\u20138.","journal-title":"A population-based cohort study Thromb Haemost"},{"issue":"10","key":"7690_CR6","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.2337\/dc21-2383","volume":"45","author":"J Dimakos","year":"2022","unstructured":"Dimakos J, Cui Y, Platt RW, Renoux C, Filion KB, Douros A. Concomitant use of sulfonylureas and warfarin and the risk of severe hypoglycemia: population-based cohort study. Diabetes Care. 2022;45(10):e131\u20133.","journal-title":"Diabetes Care"},{"issue":"2","key":"7690_CR7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.12968\/hmed.2012.73.2.106","volume":"73","author":"JW Mackay","year":"2012","unstructured":"Mackay JW, Fenech ME, Myint KS. Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin. Br J Hosp Med (Lond). 2012;73(2):106\u20137.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"2","key":"7690_CR8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bcp.14428","volume":"87","author":"AE Engell","year":"2021","unstructured":"Engell AE, Svendsen ALO, Lind BS, Andersen CL, Andersen JS, Willadsen TG, et al. Drug-drug interaction between warfarin and statins: a Danish cohort study. Br J Clin Pharmacol. 2021;87(2):694\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"7690_CR9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41397-019-0083-3","volume":"19","author":"X Li","year":"2019","unstructured":"Li X, Li D, Wu JC, Liu ZQ, Zhou HH, Yin JY. Precision dosing of warfarin: open questions and strategies. Pharmacogenomics J. 2019;19(3):219\u201329.","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"7690_CR10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1067\/mcp.2001.117444","volume":"70","author":"R Loebstein","year":"2001","unstructured":"Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al. Interindividual variability in sensitivity to warfarin\u2013Nature or nurture? Clin Pharmacol Ther. 2001;70(2):159\u201364.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"7690_CR11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11239-019-01902-0","volume":"48","author":"JL Cohen","year":"2019","unstructured":"Cohen JL, Thompson E, Sinvani L, Kozikowski A, Qiu G, Pekmezaris R, et al. Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy. J Thromb Thrombolysis. 2019;48(4):570\u20139.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"7690_CR12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","volume":"25","author":"EJ Topol","year":"2019","unstructured":"Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44\u201356.","journal-title":"Nat Med"},{"issue":"23","key":"7690_CR13","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.jacc.2018.03.521","volume":"71","author":"KW Johnson","year":"2018","unstructured":"Johnson KW, Torres Soto J, Glicksberg BS, Shameer K, Miotto R, Ali M, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71(23):2668\u201379.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"7690_CR14","volume":"10","author":"R Liu","year":"2015","unstructured":"Liu R, Li X, Zhang W, Zhou HH. Comparison of nine statistical model based warfarin pharmacogenetic dosing algorithms using the racially diverse international warfarin pharmacogenetic consortium cohort database. PLoS ONE. 2015;10(8): e0135784.","journal-title":"PLoS ONE"},{"issue":"1","key":"7690_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/pgs.13.212","volume":"15","author":"E Grossi","year":"2014","unstructured":"Grossi E, Podda GM, Pugliano M, Gabba S, Verri A, Carpani G, et al. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. Pharmacogenomics. 2014;15(1):29\u201337.","journal-title":"Pharmacogenomics"},{"key":"7690_CR16","volume":"13","author":"MF Dai","year":"2022","unstructured":"Dai MF, Li SY, Zhang JF, Wang BY, Zhou L, Yu F, et al. Warfarin anticoagulation management during the COVID-19 pandemic: the role of internet clinic and machine learning. Front Pharmacol. 2022;13: 933156.","journal-title":"Front Pharmacol"},{"key":"7690_CR17","doi-asserted-by":"crossref","unstructured":"International Warfarin Pharmacogenetics C, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753\u201364.","DOI":"10.1056\/NEJMoa0809329"},{"key":"7690_CR18","unstructured":"Vapnik V. The nature of statistical learning theory: Springer science & business media; 2013."},{"issue":"10","key":"7690_CR19","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/bioinformatics\/btr159","volume":"27","author":"E Cosgun","year":"2011","unstructured":"Cosgun E, Limdi NA, Duarte CW. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics. 2011;27(10):1384\u20139.","journal-title":"Bioinformatics"},{"key":"7690_CR20","doi-asserted-by":"crossref","first-page":"5340845","DOI":"10.1155\/2018\/5340845","volume":"2018","author":"A Sharabiani","year":"2018","unstructured":"Sharabiani A, Nutescu EA, Galanter WL, Darabi H. A new approach towards minimizing the risk of misdosing warfarin initiation doses. Comput Math Methods Med. 2018;2018:5340845.","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"7690_CR21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1022643204877","volume":"1","author":"JR Quinlan","year":"1986","unstructured":"Quinlan JR. Induction of decision trees. Mach Learn. 1986;1(1):81\u20131060.","journal-title":"Mach Learn"},{"issue":"8","key":"7690_CR22","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/bcp.15725","volume":"89","author":"AD Dunvald","year":"2023","unstructured":"Dunvald AD, Nielsen F, Olsen DA, Ernst MT, Donnelly L, Soto-Pedre E, et al. Initiation of glucose-lowering drugs reduces the anticoagulant effect of warfarin-but not through altered drug metabolism in patients with type 2 diabetes. Br J Clin Pharmacol. 2023;89(8):2529\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"7690_CR23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-021-01263-0","volume":"20","author":"CL Cheung","year":"2021","unstructured":"Cheung CL, Sing CW, Lau WCY, Li GHY, Lip GYH, Tan KCB, et al. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study. Cardiovasc Diabetol. 2021;20(1):71.","journal-title":"Cardiovasc Diabetol"},{"key":"7690_CR24","first-page":"736","volume":"6","author":"Y Hu","year":"2015","unstructured":"Hu Y, Han YT, Wei W, Li YJ, Zhang K, Gao YR, et al. Identification, isolation, and expression analysis of heat shock transcription factors in the diploid woodland strawberry Fragaria vesca. Front Plant Sci. 2015;6:736.","journal-title":"Front Plant Sci"},{"issue":"5","key":"7690_CR25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11606-015-3583-0","volume":"31","author":"MR Castro","year":"2016","unstructured":"Castro MR, Simon G, Cha SS, Yawn BP, Melton LJ 3rd, Caraballo PJ. Statin use, diabetes incidence and overall mortality in normoglycemic and impaired fasting glucose patients. J Gen Intern Med. 2016;31(5):502\u20138.","journal-title":"J Gen Intern Med"},{"key":"7690_CR26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067731","volume":"376","author":"A Hodkinson","year":"2022","unstructured":"Hodkinson A, Tsimpida D, Kontopantelis E, Rutter MK, Mamas MA, Panagioti M. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022;376: e067731.","journal-title":"BMJ"},{"issue":"4","key":"7690_CR27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4239\/wjd.v5.i4.444","volume":"5","author":"I Martin-Timon","year":"2014","unstructured":"Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444\u201370.","journal-title":"World J Diabetes"},{"key":"7690_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109980","volume":"190","author":"JS Neves","year":"2022","unstructured":"Neves JS, Newman C, Bostrom JA, Buysschaert M, Newman JD, Medina JL, et al. Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Res Clin Pract. 2022;190: 109980.","journal-title":"Diabetes Res Clin Pract"},{"key":"7690_CR29","volume":"362","author":"R Ramos","year":"2018","unstructured":"Ramos R, Comas-Cufi M, Marti-Lluch R, Ballo E, Ponjoan A, Alves-Cabratosa L, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ. 2018;362: k3359.","journal-title":"BMJ"},{"key":"7690_CR30","doi-asserted-by":"crossref","unstructured":"Eldor R, Raz I. American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care. 2009;32 Suppl 2(Suppl 2):S384\u201391.","DOI":"10.2337\/dc09-S345"},{"issue":"6","key":"7690_CR31","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.xphs.2016.03.011","volume":"105","author":"AN Shaik","year":"2016","unstructured":"Shaik AN, Bohnert T, Williams DA, Gan LL, LeDuc BW. Mechanism of drug-drug interactions between warfarin and statins. J Pharm Sci. 2016;105(6):1976\u201386.","journal-title":"J Pharm Sci"},{"issue":"2\u20133","key":"7690_CR32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1900\/RDS.2013.10.213","volume":"10","author":"YH Chang","year":"2013","unstructured":"Chang YH, Lin KC, Chang DM, Hsieh CH, Lee YJ. Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients. Rev Diabet Stud. 2013;10(2\u20133):213\u201322.","journal-title":"Rev Diabet Stud"},{"key":"7690_CR33","unstructured":"Patel S, Singh R, Preuss CV, Patel N. Warfarin. StatPearls. Treasure Island (FL): StatPearls Publishing"},{"key":"7690_CR34","unstructured":"Copyright \u00a9 2024, StatPearls Publishing LLC.; 2024."},{"key":"7690_CR35","unstructured":"Shikdar S, Vashisht R, Bhattacharya PT. International normalized ratio (INR). StatPearls. Treasure Island (FL): StatPearls Publishing"},{"issue":"1","key":"7690_CR36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12959-016-0088-y","volume":"14","author":"JR Schein","year":"2016","unstructured":"Schein JR, White CM, Nelson WW, Kluger J, Mearns ES, Coleman CI. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J. 2016;14(1):14.","journal-title":"Thromb J"},{"issue":"3","key":"7690_CR37","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.19102\/icrm.2017.080302","volume":"8","author":"JA Reiffel","year":"2017","unstructured":"Reiffel JA. Time in the therapeutic range (TTR): an overly simplified conundrum. J Innov Card Rhythm Manag. 2017;8(3):2643\u20136.","journal-title":"J Innov Card Rhythm Manag"},{"issue":"3","key":"7690_CR38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/B:THRO.0000011377.78585.63","volume":"15","author":"L Schmitt","year":"2003","unstructured":"Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15(3):213\u20136.","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"7690_CR39","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.19102\/icrm.2018.091203","volume":"9","author":"S Siddiqui","year":"2018","unstructured":"Siddiqui S, DeRemer CE, Waller JL, Gujral JS. Variability in the calculation of time in therapeutic range for the quality control measurement of warfarin. J Innov Card Rhythm Manag. 2018;9(12):3428\u201334.","journal-title":"J Innov Card Rhythm Manag"},{"issue":"1","key":"7690_CR40","doi-asserted-by":"crossref","first-page":"11647","DOI":"10.1038\/s41598-024-61664-5","volume":"14","author":"P Kosum","year":"2024","unstructured":"Kosum P, Siranart N, Nissaipan K, Laohapiboolrattana W, Sowalertrat W, Triamamornwooth K, et al. Utility of TTR-INR guided warfarin adjustment protocol to improve time in therapeutic range in patients with atrial fibrillation receiving warfarin. Sci Rep. 2024;14(1):11647.","journal-title":"Sci Rep"},{"issue":"1","key":"7690_CR41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","volume":"41","author":"DM Witt","year":"2016","unstructured":"Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):187\u2013205.","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"7690_CR42","first-page":"295","volume":"95","author":"J Wilbur","year":"2017","unstructured":"Wilbur J, Shian B. Deep venous thrombosis and pulmonary embolism: current therapy. Am Fam Physician. 2017;95(5):295\u2013302.","journal-title":"Am Fam Physician"},{"issue":"1","key":"7690_CR43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2008.09.016","volume":"124","author":"CL Morgan","year":"2009","unstructured":"Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124(1):37\u201341.","journal-title":"Thromb Res"},{"issue":"4","key":"7690_CR44","first-page":"1144","volume":"8","author":"S Kaithoju","year":"2015","unstructured":"Kaithoju S. Ischemic stroke: risk stratification, warfarin teatment and outcome measure. J Atr Fibrillation. 2015;8(4):1144.","journal-title":"J Atr Fibrillation"},{"issue":"1","key":"7690_CR45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3402\/ljm.v4i1.4809","volume":"4","author":"H Mohamed","year":"2009","unstructured":"Mohamed H. Antithrombotic therapy in patients with prosthetic heart valves. Libyan J Med. 2009;4(1):54\u20136.","journal-title":"Libyan J Med"},{"issue":"6","key":"7690_CR46","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1002\/ehf2.13597","volume":"8","author":"X Zhu","year":"2021","unstructured":"Zhu X, Wang Z, Ferrari MW, Ferrari-Kuehne K, Bulter J, Xu X, et al. Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually. ESC Heart Fail. 2021;8(6):4737\u201350.","journal-title":"ESC Heart Fail"},{"key":"7690_CR47","doi-asserted-by":"crossref","unstructured":"Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1(Suppl 1):S62\u20139.","DOI":"10.2337\/dc10-S062"},{"key":"7690_CR48","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17).","DOI":"10.3390\/ijms21176275"},{"key":"7690_CR49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fendo.2018.00002","volume":"9","author":"S De Rosa","year":"2018","unstructured":"De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne). 2018;9:2.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"7690_CR50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","volume":"21","author":"C-X Ma","year":"2022","unstructured":"Ma C-X, Ma X-N, Guan C-H, Li Y-D, Mauricio D, Fu S-B. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74.","journal-title":"Cardiovasc Diabetol"},{"key":"7690_CR51","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3389\/fphar.2019.01568","volume":"10","author":"HJ Sun","year":"2019","unstructured":"Sun HJ, Wu ZY, Nie XW, Bian JS. Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide. Front Pharmacol. 2019;10:1568.","journal-title":"Front Pharmacol"},{"key":"7690_CR52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12872-015-0124-z","volume":"15","author":"JW Yau","year":"2015","unstructured":"Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15:130.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"7690_CR53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/0003319717732238","volume":"69","author":"P Poredos","year":"2018","unstructured":"Poredos P, Jezovnik MK. Endothelial dysfunction and venous thrombosis. Angiology. 2018;69(7):564\u20137.","journal-title":"Angiology"},{"key":"7690_CR54","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.864735","volume":"9","author":"M Pilard","year":"2022","unstructured":"Pilard M, Ollivier EL, Gourdou-Latyszenok V, Couturaud F, Lemari\u00e9 CA. Endothelial cell phenotype, a major determinant of venous thrombo-inflammation. Front Cardiovasc Med. 2022;9: 864735.","journal-title":"Front Cardiovasc Med"},{"key":"7690_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2018.00001","volume":"5","author":"N Pechlivani","year":"2018","unstructured":"Pechlivani N, Ajjan RA. Thrombosis and vascular inflammation in diabetes: mechanisms and potential therapeutic targets. Front Cardiovasc Med. 2018;5:1.","journal-title":"Front Cardiovasc Med"},{"key":"7690_CR56","unstructured":"Braunwald E, Mann DL, Zipes DP, Libby P, Bonow R. Braunwald\u2019s heart disease: a textbook of cardiovascular medicine. Braunwald\u2019s heart disease: A textbook of cardiovascular medicine2015. p. 1028-."},{"issue":"5","key":"7690_CR57","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/VHRM.S3920","volume":"4","author":"M Kalani","year":"2008","unstructured":"Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag. 2008;4(5):1061\u20138.","journal-title":"Vasc Health Risk Manag"},{"issue":"8","key":"7690_CR58","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1538-7836.2004.00836.x","volume":"2","author":"P Ferroni","year":"2004","unstructured":"Ferroni P, Basili S, Falco A, Dav\u00ec G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2(8):1282\u201391.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"7690_CR59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2337\/dc08-1865","volume":"32","author":"DJ Schneider","year":"2009","unstructured":"Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32(4):525\u20137.","journal-title":"Diabetes Care"},{"issue":"4","key":"7690_CR60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1479164110383994","volume":"7","author":"JL Ferreiro","year":"2010","unstructured":"Ferreiro JL, G\u00f3mez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res. 2010;7(4):251\u20139.","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"7690_CR61","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1253\/circj.CJ-16-0208","volume":"80","author":"Y Park","year":"2016","unstructured":"Park Y, Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for secondary prevention in patients with diabetes mellitus and coronary artery disease. Circ J. 2016;80(4):791\u2013801.","journal-title":"Circ J"},{"issue":"7","key":"7690_CR62","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.amjmed.2011.12.004","volume":"125","author":"G Piazza","year":"2012","unstructured":"Piazza G, Goldhaber SZ, Kroll A, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in patients with diabetes mellitus. Am J Med. 2012;125(7):709\u201316.","journal-title":"Am J Med"},{"key":"7690_CR63","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110190","volume":"194","author":"C Deischinger","year":"2022","unstructured":"Deischinger C, Dervic E, Nopp S, Kaleta M, Klimek P, Kautzky-Willer A. Diabetes mellitus is associated with a higher relative risk for venous thromboembolism in females than in males. Diabetes Res Clin Pract. 2022;194: 110190.","journal-title":"Diabetes Res Clin Pract"},{"key":"7690_CR64","doi-asserted-by":"crossref","unstructured":"Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, Preckel B. Effects of hyperglycemia and diabetes mellitus on coagulation and hemostasis. J Clin Med. 2021;10(11).","DOI":"10.3390\/jcm10112419"},{"issue":"1","key":"7690_CR65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.1146","volume":"105","author":"YH Nam","year":"2019","unstructured":"Nam YH, Brensinger CM, Bilker WB, Leonard CE, Han X, Hennessy S. Serious hypoglycemia and use of warfarin in combination with sulfonylureas or metformin. Clin Pharmacol Ther. 2019;105(1):210\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"7690_CR66","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/560108","volume":"2015","author":"A Sharabiani","year":"2015","unstructured":"Sharabiani A, Bress A, Douzali E, Darabi H. Revisiting warfarin dosing using machine learning techniques. Comput Math Methods Med. 2015;2015: 560108.","journal-title":"Comput Math Methods Med"},{"issue":"2","key":"7690_CR67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315\u201352.","journal-title":"Chest"},{"issue":"4","key":"7690_CR68","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/cpt.3049","volume":"115","author":"QY Li","year":"2024","unstructured":"Li QY, Tang BH, Wu YE, Yao BF, Zhang W, Zheng Y, et al. Machine learning: a new approach for dose individualization. Clin Pharmacol Ther. 2024;115(4):727\u201344.","journal-title":"Clin Pharmacol Ther"},{"key":"7690_CR69","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fphar.2019.01550","volume":"10","author":"A Roche-Lima","year":"2019","unstructured":"Roche-Lima A, Roman-Santiago A, Feliu-Maldonado R, Rodriguez-Maldonado J, Nieves-Rodriguez BG, Carrasquillo-Carrion K, et al. Machine learning algorithm for predicting warfarin dose in Caribbean Hispanics using pharmacogenetic data. Front Pharmacol. 2019;10:1550.","journal-title":"Front Pharmacol"},{"issue":"2","key":"7690_CR70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.18773\/austprescr.2015.016","volume":"38","author":"PA Tideman","year":"2015","unstructured":"Tideman PA, Tirimacco R, St John A, Roberts GW. How to manage warfarin therapy. Aust Prescr. 2015;38(2):44\u20138.","journal-title":"Aust Prescr"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07690-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07690-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07690-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:03:43Z","timestamp":1773698623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07690-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7690"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07690-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}